Regulation of alveolar gas conductance by NO in man, as based on studies with NO donors and inhibitors of NO production

Acta Physiol (Oxf). 2009 Jun;196(2):267-77. doi: 10.1111/j.1748-1716.2008.01939.x. Epub 2008 Nov 19.

Abstract

Aim: Nitric oxide (NO) is a mediator of the pulmonary vessel tone and permeability. We hypothesized that it may also regulate the alveolar-capillary membrane gas conductance and lung diffusion capacity.

Methods: In 20 healthy subjects (age = 23 +/- 3 years) we measured lung diffusion capacity for carbon monoxide (DLco), its determinants (membrane conductance, D(m), and pulmonary capillary blood volume, V(c)), systolic pulmonary artery pressure (PAPs) and pulmonary vascular resistance (PVR). Measurements were performed before and after administration of N(g)-monomethyl-L-arginine (L-NMMA, 0.5 mg kg(-1) min(-1)), as a NO production inhibitor, and L-arginine (L-Arg, 0.5 mg kg(-1) min(1)) as a NO pathway activator. The effects of L-NMMA were also tested in combination with active L-Arg and inactive stereoisomer D-Arg vehicled by 150 mL of 5%d-glucose solution. For L-Arg and L-NMMA, saline (150 mL) was also tested as a vehicle.

Results: L-NMMA reduced D(m) (-41%P < 0.01), DLco (-20%, P < 0.01) and cardiac output (CO), and increased PAPs and PVR. In 10 additional subjects, a dose of L-NMMA of 0.03 mg kg(-1) min(1) infused in the main stem of the pulmonary artery was able to lower D(m) (-32%, P < 0.01) despite no effect on PVR and CO. D(m) depression was significantly greater when L-NMMA was vehicled by saline than by glucose. L-Arg but not D-Arg abolished the effects of L-NMMA. L-Arg alone increased D(m) (+14%, P < 0.01).

Conclusion: The findings indicate that NO mediates the respiratory effects of L-NMMA and L-Arg, and is involved in the physiology of the alveolar-capillary membrane gas conductance in humans. NO deficiency may cause an excessive endothelial sodium exchange/water conduction and fluid leakage in alveolar interstitial space, lengthening the air-blood path and depressing diffusion capacity.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Arginine / pharmacology
  • Blood Pressure / drug effects
  • Blood Pressure / physiology
  • Breath Tests
  • Carbon Monoxide / metabolism
  • Enzyme Inhibitors / pharmacology*
  • Humans
  • Lung Volume Measurements
  • Male
  • Nitric Oxide / biosynthesis
  • Nitric Oxide / metabolism*
  • Nitric Oxide Donors / pharmacology*
  • Nitric Oxide Synthase / antagonists & inhibitors*
  • Pharmaceutical Vehicles / pharmacology
  • Pulmonary Circulation / drug effects
  • Pulmonary Circulation / physiology
  • Pulmonary Diffusing Capacity / drug effects
  • Pulmonary Diffusing Capacity / physiology
  • Pulmonary Gas Exchange / drug effects
  • Pulmonary Gas Exchange / physiology*
  • Vascular Resistance / drug effects
  • Vascular Resistance / physiology
  • Young Adult
  • omega-N-Methylarginine / pharmacology

Substances

  • Enzyme Inhibitors
  • Nitric Oxide Donors
  • Pharmaceutical Vehicles
  • omega-N-Methylarginine
  • Nitric Oxide
  • Carbon Monoxide
  • Arginine
  • Nitric Oxide Synthase